Clinical Trial

Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension) for PET/CT imaging assessments in patients with metastatic/advanced gynecological tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-08.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT06977126
Lead Sponsor University Health Network, Toronto
Conditions Gynecological Cancers
Enrollment 24 participants
Start Date 2025-11-18
Primary Completion 2026-11-18 (estimated)
Study Completion 2027-11-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-08